StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.19+0.04 (+0.10%)

Close on Nov 18, 2026Market cap $3.89BP/E –Yield –

CRISPR Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

CRISPR Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$534.34M. For fiscal 2025 it was -$664.57M. The highest annual figure on record is $373.53M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$664.57M–
FY2024Dec 31, 2024-$466.57M–
FY2023Dec 31, 2023-$222.54M–
FY2022Dec 31, 2022-$673.16M-280.2%
FY2021Dec 31, 2021$373.53M–
FY2020Dec 31, 2020-$354.44M-858.3%
FY2019Dec 31, 2019$46.74M–
FY2018Dec 31, 2018-$158.94M–
FY2017Dec 31, 2017-$64.65M–
FY2016Dec 31, 2016-$68.13M–
FY2015Dec 31, 2015-$25.73M–
FY2014Dec 31, 2014-$6.63M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$117.27M–
Q1 FY2026Mar 31, 2026-$130.25M–
Q4 FY2025Dec 31, 2025-$154.76M–
Q3 FY2025Sep 30, 2025-$132.06M–
Q2 FY2025Jun 30, 2025-$229.32M–
Q1 FY2025Mar 31, 2025-$148.42M–
Q4 FY2024Dec 31, 2024-$64.59M-192.8%
Q3 FY2024Sep 30, 2024-$110.13M–
Q2 FY2024Jun 30, 2024-$151.26M–
Q1 FY2024Mar 31, 2024-$140.59M–
Q4 FY2023Dec 31, 2023$69.58M–
Q3 FY2023Sep 30, 2023-$132.41M–
Q2 FY2023Jun 30, 2023-$95.22M–
Q1 FY2023Mar 31, 2023-$64.49M–
Q4 FY2022Dec 31, 2022-$131.54M–
Q3 FY2022Sep 30, 2022-$182.39M–
Q2 FY2022Jun 30, 2022-$183.26M-124.0%
Q1 FY2022Mar 31, 2022-$175.97M–
Q4 FY2021Dec 31, 2021-$145.70M–
Q3 FY2021Sep 30, 2021-$128.85M–
Q2 FY2021Jun 30, 2021$762.62M–
Q1 FY2021Mar 31, 2021-$114.54M–
Q4 FY2020Dec 31, 2020-$107.76M-1081.2%
Q3 FY2020Sep 30, 2020-$92.40M-166.4%
Q2 FY2020Jun 30, 2020-$80.69M–
Q1 FY2020Mar 31, 2020-$73.59M–
Q4 FY2019Dec 31, 2019$10.98M–
Q3 FY2019Sep 30, 2019$139.16M–
Q2 FY2019Jun 30, 2019-$54.98M–
Q1 FY2019Mar 31, 2019-$48.42M–
Q4 FY2018Dec 31, 2018-$45.23M-4753.1%
Q3 FY2018Sep 30, 2018-$49.43M–
Q2 FY2018Jun 30, 2018-$37.29M–
Q1 FY2018Mar 31, 2018-$27.00M–
Q4 FY2017Dec 31, 2017$972.00K–
Q3 FY2017Sep 30, 2017-$23.57M–
Q2 FY2017Jun 30, 2017-$21.31M–
Q1 FY2017Mar 31, 2017-$20.74M–
Q4 FY2016Dec 31, 2016-$25.31M–
Q3 FY2016Sep 30, 2016-$14.61M–

More CRISPR Therapeutics figures

See a number that looks wrong?